(Q37974873)

English

US Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparins

scientific article published on April 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

US Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparins (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

0 references

Gilles Montalescot

4

object named as

Gilles Montalescot

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

author name string

Marc Cohen

1

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Walter P Jeske

2

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Jose C Nicolau

3

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Jawed Fareed

5

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 April 2012

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Journal of Thrombosis and Thrombolysis

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

33

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

230-238

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Contaminated heparin associated with adverse clinical events and activation of the contact system

1 reference

https://api.crossref.org/works/10.1007%2FS11239-012-0680-3

21 January 2018

Pharmacokinetic and pharmacodynamic properties of oral anticoagulants, especially phenprocoumon

1 reference

https://api.crossref.org/works/10.1007%2FS11239-012-0680-3

21 January 2018

Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins

1 reference

https://api.crossref.org/works/10.1007%2FS11239-012-0680-3

21 January 2018

A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS11239-012-0680-3

21 January 2018

Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction

1 reference

https://api.crossref.org/works/10.1007%2FS11239-012-0680-3

21 January 2018

Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1007%2FS11239-012-0680-3

21 January 2018

Differences among low-molecular-weight heparins: evidence in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1007%2FS11239-012-0680-3

21 January 2018

Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: the EVET trial

1 reference

https://api.crossref.org/works/10.1007%2FS11239-012-0680-3

21 January 2018

Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: results of the enoxaparin versus tinzaparin (EVET) trial at 6 months

1 reference

https://api.crossref.org/works/10.1007%2FS11239-012-0680-3

21 January 2018

Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study).

1 reference

https://api.crossref.org/works/10.1007%2FS11239-012-0680-3

21 January 2018

ACCF/AHA 2011 health policy statement on therapeutic interchange and substitution: a report of the American College of Cardiology Foundation Clinical Quality Committee

1 reference

https://api.crossref.org/works/10.1007%2FS11239-012-0680-3

21 January 2018

The shortage of essential chemotherapy drugs in the United States.

1 reference

https://api.crossref.org/works/10.1007%2FS11239-012-0680-3

21 January 2018

The reality of drug shortages--the case of the injectable agent propofol

1 reference

https://api.crossref.org/works/10.1007%2FS11239-012-0680-3

21 January 2018

Shattuck lecture. Innovation, regulation, and the FDA.

1 reference

https://api.crossref.org/works/10.1007%2FS11239-012-0680-3

21 January 2018

From the Food and Drug Administration

1 reference

https://pubmed.ncbi.nlm.nih.gov/22234748

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Are the available low-molecular-weight heparin preparations the same?

1 reference

https://pubmed.ncbi.nlm.nih.gov/22234748

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Four-dollar generics--increased accessibility, impaired quality assurance

1 reference

https://pubmed.ncbi.nlm.nih.gov/22234748

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Heterogeneity of unfractionated heparins studied in connection with species, source, and production processes

1 reference

https://pubmed.ncbi.nlm.nih.gov/22234748

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Production and chemical processing of low molecular weight heparins.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22234748

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biosimilar therapeutics-what do we need to consider?

1 reference

https://pubmed.ncbi.nlm.nih.gov/22234748

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Drug shortages--a critical challenge for the generic-drug market

1 reference

https://pubmed.ncbi.nlm.nih.gov/22234748

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Few bicyclic acetals at reducing end of low-molecular-weight heparins: might they restrict specification of pharmacopoeia?

1 reference

https://pubmed.ncbi.nlm.nih.gov/22234748

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regulation of follow-on biologics

1 reference

https://pubmed.ncbi.nlm.nih.gov/22234748

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Scientific and legal viability of follow-on protein drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/22234748

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The FDA's assessment of follow-on protein products: a historical perspective

1 reference

https://pubmed.ncbi.nlm.nih.gov/22234748

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A proposal for radical changes in the drug-approval process

1 reference

https://pubmed.ncbi.nlm.nih.gov/22234748

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11239-012-0680-3

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37974873&oldid=2201128330"